Strategies for Improving Adherence to Oral Oncolytics



"At IU Health, we speak to patients at initial education, so before they start the medication, and then we follow up with every cycle. So depending on the oral agent they're on, that may be 3 weeks or it may be 6 weeks, it depends on the patient. And our role in that is making sure we're assessing adherence, so answering any questions that they may have, reiterating how they should take the drug (with or without food), and then assessing obviously any medication changes, interactions, and adverse events. We do that on a cycle basis right now, so that is a pharmacist speaking to those patients."

Most Popular

Related Articles

The approval of ivosidenib fills an unmet need for patients with relapsed or refractory acute myeloid leukemia who have an IDH1 genetic mutation.
Gene-editing technology could lead to new targeted therapies and help clinicians catch developing cancers before they metastasize.
Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$